What does a clear ma­jor­i­ty of the bio­phar­ma in­dus­try think of the FDA ap­proval of ad­u­canum­ab? 'Hor­ri­fy­ing' 'Dan­ger­ous' 'Con­fus­ing' 'Dis­as­ter'

Over the years, we’ve be­come used to see­ing a con­sen­sus emerge ear­ly in our in­dus­try polls at End­points News. And when we took the pulse of drug hunters on the heels of a con­tro­ver­sial FDA ap­proval for ad­u­canum­ab this week, it be­came im­me­di­ate­ly ap­par­ent that the vast ma­jor­i­ty of our read­ers — heav­i­ly con­cen­trat­ed among bio­phar­ma staffers and ex­ecs — were in­censed by what they had just wit­nessed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.